|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Small-scale clinical trials have proven the efficacy and safety of recombinant AM peptide therapy for heart failure.
|
29577955 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Adrenomedullin in heart failure: pathophysiology and therapeutic application.
|
30592365 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure.
|
30843353 |
2019 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission.
|
31797505 |
2019 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Based on these findings, it may be concluded that, compared with MSCs, MSCs overexpressing ADM can further improve heart function in rats experiencing heart failure through enhanced antifibrotic activity.
|
29138835 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
All molecular forms of AM are prognostic markers for heart failure.
|
29153200 |
2018 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Adrenomedullin (ADM) correlates with adverse cardiovascular outcomes in patients with acute myocardial infarction (AMI) and in patients with heart failure.
|
26766169 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Receiver operating characteristic curves yielded an area under the curve of 1.00 (p<0.001) for UCN1, 1.00 (p<0.001) for ADM, and 0.99 (p<0.001) for pro-BNP in the diagnosis of HF.
|
25868038 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Second, this review explores other hormones that are augmented by sacubitril/valsartan such as bradykinin, substance P and adrenomedullin that may contribute to the efficacy of sacubitril/valsartan in HF.
|
28689178 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this review, seven groups of biomarkers associated to myocardial stretch (mid-regional proatrial natriuretic peptide, MR-proANP), myocyte injury (high-sensitive troponins, hs-cTn; heart-type fatty acid-binding protein, H-FABP; glutathione transferase P1, GSTP1), matrix remodeling (galectin-3; soluble isoform of suppression of tumorigenicity 2, sST2), inflammation (growth differentiation factor-15, GDF-15), renal dysfunction (neutrophil gelatinase-associated lipocalin, NGAL; kidney injury molecule-1, KIM-1), neurohumoral activation (adrenomedullin, MR-proADM; copeptin), and oxidative stress (ceruloplasmin; myeloperoxidase, MPO; 8-hydroxy-2'-deoxyguanosine, 8-OHdG; thioredoxin 1, Trx1) in HF will be overviewed.
|
28212715 |
2017 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Mid-regional pro-adrenomedullin and ST2 in heart failure: Contributions to diagnosis and prognosis.
|
28606358 |
2017 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Further, plasma AM levels are increased in patients with various cardiovascular diseases, including hypertension, heart failure and renal failure.
|
16616959 |
2006 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
LHGDN |
Collectively, these results support a protective role for increased AM in the cardiac hypertrophy and heart failure.
|
15974887 |
2005 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Increased plasma levels of adrenomedullin (ADM) have been reported in patients with congestive heart failure Immunohistochemical ADM has been identified in failing human ventricle, but the gene expression pattern of ADM messenger RNA (mRNA) in myocardial tissue of patients with heart failure has not been elucidated.
|
15539129 |
2004 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
RGD |
These results suggest that induction of the cardiac AM system, including the ligand, receptor, and amidating activity, may modulate pathophysiology during the transition from LVH to HF in this model.
|
12623952 |
2003 |
|
Heart failure
|
0.300 |
Biomarker
|
disease |
BEFREE |
Cessation of pulmonary and coronary secretion of adrenomedullin peptides in the progression of human heart failure.
|
11972292 |
2002 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
LHGDN |
Cessation of pulmonary and coronary secretion of adrenomedullin peptides in the progression of human heart failure.
|
11972292 |
2002 |
|
Heart failure
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The actions of adrenomedullin and the activation of this peptide in cardiovascular disease suggest it may have an important pathophysiologic role in heart failure.
|
11305974 |
2001 |